Search
Verrica Pharmaceuticals Inc
VRCAAdd to Watchlist
6.135USD
+0.195+3.28%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
105.39MMarket Cap
LossP/E TTM
More Details of Verrica Pharmaceuticals Inc Company
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
Verrica Pharmaceuticals Inc Info
Ticker SymbolVRCA
Company nameVerrica Pharmaceuticals Inc
IPO dateJun 15, 2018
CEORieger (Jayson)
Number of employees71
Security typeOrdinary Share
Fiscal year-endJun 15
Address44 West Gay Street
CityWEST CHESTER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19380
Phone14844533300
Websitehttps://verrica.com/
Ticker SymbolVRCA
IPO dateJun 15, 2018
CEORieger (Jayson)
Company Executives of Verrica Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jayson Rieger
Dr. Jayson Rieger
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
183.29K
-0.00%
Mr. David Zawitz
Mr. David Zawitz
Chief Operating Officer
Chief Operating Officer
21.00K
+47.62%
Dr. Noah L. Rosenberg, M.D.
Dr. Noah L. Rosenberg, M.D.
Chief Medical Officer
Chief Medical Officer
2.36K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00
--
Dr. Gavin Corcoran
Dr. Gavin Corcoran
Independent Director
Independent Director
2.00
--
Mr. Paul B. Manning
Mr. Paul B. Manning
Chairman of the Board
Chairman of the Board
--
--
Mr. Mark A. Prygocki, Sr.
Mr. Mark A. Prygocki, Sr.
Independent Director
Independent Director
--
--
Dr. Lawrence Eichenfield, M.D.
Dr. Lawrence Eichenfield, M.D.
Independent Director
Independent Director
--
--
Mr. John J. Kirby
Mr. John J. Kirby
Interim Chief Financial Officer, Interim Principal Financial Officer
Interim Chief Financial Officer, Interim Principal Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jayson Rieger
Dr. Jayson Rieger
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
183.29K
-0.00%
Mr. David Zawitz
Mr. David Zawitz
Chief Operating Officer
Chief Operating Officer
21.00K
+47.62%
Dr. Noah L. Rosenberg, M.D.
Dr. Noah L. Rosenberg, M.D.
Chief Medical Officer
Chief Medical Officer
2.36K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00
--
Dr. Gavin Corcoran
Dr. Gavin Corcoran
Independent Director
Independent Director
2.00
--
Mr. Paul B. Manning
Mr. Paul B. Manning
Chairman of the Board
Chairman of the Board
--
--
FAQs
Who are the top five shareholders of Verrica Pharmaceuticals Inc?
The top five shareholders of Verrica Pharmaceuticals Inc are: Dr. Jayson Rieger
How many institutions hold shares of Verrica Pharmaceuticals Inc (VRCA)?
As of 2026Q1, 180 institutions hold shares of Verrica Pharmaceuticals Inc, with a combined market value of approximately 5.43M, accounting for 31.63% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1273710.00.